Unsere Publikationen

Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management

Link
https://doi.org/10.1177/1352458518816612
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Cuker A, Bass AD, Nadj C, Agius MA, Steingo B, Selmaj KW, Thoits T, Guerreiro A, Van Wijmeersch B, Ziemssen T, Meuth SG, LaGanke CC, Thangavelu K, Rodriguez CE, Baker DP, Margolin DH, Jannsens A.
Verlag
Mult Scler. 2020 Jan;26(1):48-56.
Zum Eintrag

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

Link
https://doi.org/10.1177/2055217320972137
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Horáková D, Boster A, Bertolotto A, Freedman MS, Firmino I, Cavalier SJ, Jacobs AK, Thangavelu K, Daizadeh N, Poole EM, Baker DP, Margolin DH, Ziemssen T; CARE-MS I, CARE-MS II, and CAMMS03409 Investigators.
Verlag
Mult Scler J Exp Transl Clin. 2020 Dec 18;6(4):2055217320972137.
Zum Eintrag

Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis

Link
https://doi.org/10.1016/j.msard.2019.101503
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Lau AY, Lui GCY, Chan K-, Au C, Mok VCT, Ziemssen T.
Verlag
Mult Scler Relat Disord 2020;38.
Zum Eintrag

Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study

Link
https://doi.org/10.1007/s40263-020-00700-0
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Naismith RT, Wundes A, Ziemssen T, Jasinska E, Freedman MS, Lembo AJ, Selmaj K, Bidollari I, Chen H, Hanna J, Leigh-Pemberton R, Lopez-Bresnahan M, Lyons J, Miller C, Rezendes D, Wolinsky JS; EVOLVE-MS-2 Study Group.
Verlag
CNS Drugs. 2020 Feb;34(2):185-196.
Zum Eintrag

Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts - The CONFIDENCE study protocol

Link
https://doi.org/10.1186/s12883-020-01667-7
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Dirks P, Zingler V, Leemhuis J, Berthold H, Hieke-Schulz S, Wormser D, Ziemssen T.
Verlag
BMC Neurol. 2020 Mar 14;20(1):95.
Zum Eintrag

Long-term real-world evidence for sustained clinical benefits of fingolimod following switch from natalizumab

Link
https://doi.org/10.1016/j.msard.2019.101893
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Cornelissen C, Ettle B; PANGAEA Study Group.
Verlag
Mult Scler Relat Disord. 2020 Apr;39:101893.
Zum Eintrag

Letter to the editor regarding “Therapeutic drug monitoring of natalizumab”

Link
https://doi.org/10.1177/1352458519837702
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Proschmann U, Sehr T, Akgün K, Ziemssen T.
Verlag
Mult Scler J 2020;26(6):741-742.
Zum Eintrag

Fingolimod Leads to Immediate Immunological Changes Within 6 h After First Administration

Link
https://doi.org/10.3389/fneur.2020.00391
Tags
Multiple SkleroseMS Behandlung
Jahr
2020
Autoren
Sehr T, Akgün K, Haase R, Ziemssen T.
Verlag
Front Neurol 2020;11.
Zum Eintrag

Publikationen durchsuchen

Publikationen filtern

Filter
Tags
Multiple Sklerose
MS Behandlung
Mobilität
Autonomes Nervensystem & Neuroendokrinologie
Neuroimmunologie
Herzratenvariabilität
Baroreflexsensitivität
Management & Science
eHealth
Gesundheitsökonomie
Andere
Zeige alleVerstecke
Jahr
-